Get the Stockscreener App
1.89
5.03%
-0.10
Pre-market:
1.90
0.01
+0.53%
Annovis Bio Inc stock is traded at $1.89, with a volume of 1.40M.
It is down -5.03% in the last 24 hours and down -16.74% over the past month.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
See More
Previous Close:
$1.99
Open:
$1.94
24h Volume:
1.40M
Relative Volume:
1.33
Market Cap:
$80.40M
Revenue:
-
Net Income/Loss:
$-40.92M
P/E Ratio:
-1.1009
EPS:
-1.7167
Net Cash Flow:
$-26.53M
1W Performance:
-1.56%
1M Performance:
-16.74%
6M Performance:
-58.46%
1Y Performance:
-38.03%
1-Day Range:
$1.85
$1.96
1-Week Range:
$1.78
$2.065
52-Week Range:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.89 | 84.66M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio Price, ANVS Price, Live Charts, and Marketcap - Coinbase
Annovis Regains NYSE Compliance Ahead of Listing Deadline - MyChesCo
Top Annovis Bio (ANVS) Competitors 2026 - MarketBeat
Maxim Group Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Annovis Bio (ANVS) Faces Selling Pressure: Key Levels in Focus After 7.6% DeclineVolume Rate Change - thelegaladvocate.com
Annovis Bio regains NYSE listing compliance - MSN
Annovis Bio regains NYSE listing compliance By Investing.com - Investing.com Nigeria
Annovis Bio Regains NYSE Listing Compliance - The Manila Times
Annovis launches proposed public stock and warrant offering - MSN
Annovis Bio Analyst Ratings and Price Targets | NYSE:ANVS - Benzinga
Annovis Bio director Michael Hoffman buys $142,778 in shares By Investing.com - Investing.com Australia
Annovis Bio director Michael Hoffman buys $142,778 in shares - Investing.com UK
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Annovis Bio (ANVS) Rebounds 5.39%, Tests Key Resistance After Broader Market Upward MomentumCorrective Wave - thelegaladvocate.com
Director Michael Hoffman adds 76,344 Annovis Bio (ANVS) shares in open-market buys - Stock Titan
Annovis Bio prices $15 million public offering at $1.90 - Investing.com UK
Annovis Bio Announces Dilutive Equity Offering for Trials - TipRanks
Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity - TradingView
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Annovis Bio (NYSE: ANVS) raises $13.8M via 7.895M-share offering and warrants - Stock Titan
Annovis Bio Prices $15 Million Public Offering to Fund Neurodegenerative Disease Trials - MEXC
Annovis Bio slips after pricing $15M equity offering - MSN
Annovis announces pricing of $15.0 million public offering of common stock and accompanying warrants - marketscreener.com
Annovis Bio prices $15 million public offering at $1.90 By Investing.com - Investing.com South Africa
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - The Manila Times
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Press Release: Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio Launches Proposed Stock, Warrant Offering; Shares Fall - Moomoo
Annovis Bio stock tumbles on public offering announcement By Investing.com - Investing.com India
Annovis Bio announces public offering of stock and warrants By Investing.com - Investing.com South Africa
Annovis Bio (ANVS) registers equity units with detachable warrants in shelf supplement - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Annovis Bio stock tumbles on public offering announcement - Investing.com
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annovis Bio Inc Stock (ANVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoffman Michael B | Director |
Apr 02 '26 |
Buy |
2.10 |
713,800 |
1,498,980 |
3,288,539 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):